Stocksigma LogoStocksigma Logo

Supriya Lifescience Reports Q2 FY27 Results and Expansion Updates

Supriya Lifescience reported Q2 FY27 revenue of INR 2,063.0 Mn, up 3.2% YoY (8.7% QoQ), while EBITDA dropped 37.5% YoY to INR 454.0 Mn, with margins

Supriya Lifescience Reports Q2 FY27 Results and Expansion Updates

Supriya Lifescience Ltd 路 Investor Presentation 路 06 Nov 2026, 6:53 pm

Supriya Lifescience Reports Q2 FY27 Results and Expansion Updates Supriya Lifescience reported Q2 FY27 revenue of INR 2,063.0 Mn, up 3.2% YoY (8.7% QoQ), while EBITDA dropped 37.5% YoY to INR 454.0 Mn, with margins contracting 1,435 bps YoY to 22.0%. PAT fell 42.0% YoY to INR 292.5 Mn (14.2% margin). For H1 FY27, revenue reached INR 3,960.4 Mn (up 14.8% YoY), and PAT stood at INR 532.9 Mn. The company launched two inhalation anesthetics from Ambernath, is developing GLP-1 products, patented a novel Semaglutide formulation, and plans six EU dossier filings in FY27.

Original exchange filing (PDF)

More announcements from Supriya Lifescience Ltd

All Supriya Lifescience Ltd announcements